Arbutus Biopharma Corporation
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replicaā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.86
Price+0.94%
$0.05
1Y
Price
Market Cap
$933.054m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1457.1%
EBITDA Margin-1463.5%
Net Profit Margin-1099.6%
Free Cash Flow Margin-1457.1%
EBITDA Margin-1463.5%
Net Profit Margin-1099.6%
Free Cash Flow MarginRevenue
$14.606m
+136.7%
1y CAGR+5.7%
3y CAGR+68.1%
5y CAGREarnings
-$42.277m
+39.5%
1y CAGR+12.9%
3y CAGR+11.9%
5y CAGREPS
-$0.22
+42.1%
1y CAGR+20.0%
3y CAGR+24.3%
5y CAGRBook Value
$77.399m
$97.710m
Assets$20.311m
Liabilities$922k
DebtDebt to Assets
0.9%
-
Debt to EBITDAFree Cash Flow
-$45.358m
+30.3%
1y CAGR-29.0%
3y CAGR-9.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company